ClinicalTrials.Veeva

Menu

VExUS in Ards Patients and Association with AKI (VEXAKI)

A

Assistance Publique - Hôpitaux de Paris

Status

Enrolling

Conditions

Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS)

Study type

Observational

Funder types

Other

Identifiers

NCT06805409
APHP240897

Details and patient eligibility

About

A single-center prospective observational study will be conducted with the aim of determining the prevalence of venous congestion during ARDS using venous Doppler and the VExUS score.

Full description

Acute kidney injury (AKI) is common in patients with acute respiratory distress syndrome (ARDS) and is associated with higher mortality rates. Among the mechanisms underlying this AKI, venous congestion seems to be significant. However, methods for assessing congestion are limited and may be unreliable. The use of venous Doppler (inferior vena cava, suprahepatic veins, portal vein, and intrarenal veins) for grading the severity of congestion using the Venous Excess Ultrasound Score (VExUS) could potentially enable the earlier identification of ARDS patients with congestion.

A prospective observational monocenter study will be conducted with the objective to determine the prevalence of venous congestion during ARDS using venous Doppler and the VExUS score.

The primary outcome measure will be the proportion of patients with a VExUS score ≥ 1 within 48 hours following the initiation of invasive mechanical ventilation. The secondary objective is to evaluate the association of different VExUS grades with the occurrence of the composite endpoint of major kidney events at Day 30 (MAKE-30), defined as the occurrence of death, dependence on dialysis, or persistent elevation of creatinine ≥ 200% of baseline creatinine.

The study involves adult patients admitted to the intensive care unit with moderate to severe ARDS requiring mechanical ventilation for less than 48 hours and requiring hemodynamic support with catecholamines. Within 48 hours of initiating invasive mechanical ventilation, concurrently with the cardiac ultrasound, the multi-site venous Doppler will be performed. Demographical, clinical, and biological data will be prospectively collected. The multi-site venous Doppler will be repeated on Day 7 of mechanical ventilation initiation or during catecholamine weaning, depending on which event occurs first. Patients will be followed for the entire duration of their intensive care unit stay. For patients discharged alive from the intensive care unit, follow-up will continue until 3 months after discharge to assess the occurrence of chronic kidney disease following the initial hospitalization.

No other investigations are mandated by the protocol besides performing the multi-site venous Doppler.

Enrollment

120 estimated patients

Sex

All

Ages

18 to 100 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Patients ≥18 years old
  • Moderate to severe ARDS according to the Berlin definition
  • Requiring catecholamine support
  • Undergoing invasive mechanical ventilation for less than 48 hours

Exclusion criteria

  • Patients presenting with acute kidney injury KDIGO III requiring renal replacement therapy before the initial ultrasound evaluation
  • Requirement for veno-venous or veno-arterial ECMO circulatory support before inclusion
  • Patients with end-stage chronic kidney disease, on dialysis, and/or kidney transplant recipients
  • History of Child C cirrhosis and/or liver transplantation and/or portal hypertension
  • History of portal thrombosis
  • Known history of pulmonary hypertension
  • Pregnant women
  • Patients under legal protection
  • Patients who have expressed opposition to participating in the research

Trial contacts and locations

1

Loading...

Central trial contact

Armand MEKONTSO DESSAP, MD; Romain ARRESTIER, PHD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems